PUBLICATION: 
Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6.
AUTHORS:
Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group
SUMMARY:
This substudy showed that NAT significantly altered the genomic signature of the patient’s breast cancer compared with the patient’s pre-treatment genomic profile. These alterations occurred in a subtype-dependent manner, suggesting that NAT may have either eliminated the most susceptible tumor subclone, leaving the treatment resistant clone with a different genetic signature, or altered molecular characteristics of the original cancer.
